NZ753020B2 - Pyridone compound as c-met inhibitor - Google Patents
Pyridone compound as c-met inhibitor Download PDFInfo
- Publication number
- NZ753020B2 NZ753020B2 NZ753020A NZ75302017A NZ753020B2 NZ 753020 B2 NZ753020 B2 NZ 753020B2 NZ 753020 A NZ753020 A NZ 753020A NZ 75302017 A NZ75302017 A NZ 75302017A NZ 753020 B2 NZ753020 B2 NZ 753020B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- acid
- acceptable salt
- group
- pharmaceutically acceptable
- Prior art date
Links
- -1 Pyridone compound Chemical class 0.000 title claims description 17
- 230000002401 inhibitory effect Effects 0.000 title abstract description 20
- 239000003112 inhibitor Substances 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 239000011780 sodium chloride Substances 0.000 claims abstract description 54
- 150000003839 salts Chemical class 0.000 claims abstract description 50
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 13
- 125000005842 heteroatoms Chemical group 0.000 claims description 12
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 102100004109 HEY1 Human genes 0.000 claims description 6
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 6
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 6
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- MAUMSNABMVEOGP-UHFFFAOYSA-N (methyl-$l^{2}-azanyl)methane Chemical compound C[N]C MAUMSNABMVEOGP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000543 intermediate Substances 0.000 description 71
- 239000000243 solution Substances 0.000 description 52
- 238000006243 chemical reaction Methods 0.000 description 34
- 210000004027 cells Anatomy 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 28
- 239000000203 mixture Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000002253 acid Substances 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 125000004429 atoms Chemical group 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 235000011152 sodium sulphate Nutrition 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 239000012299 nitrogen atmosphere Substances 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 9
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 9
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- AHYMHWXQRWRBKT-UHFFFAOYSA-N Tepotinib Chemical compound C1CN(C)CCC1COC1=CN=C(C=2C=C(CN3C(C=CC(=N3)C=3C=C(C=CC=3)C#N)=O)C=CC=2)N=C1 AHYMHWXQRWRBKT-UHFFFAOYSA-N 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drugs Drugs 0.000 description 7
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 6
- 229950009455 Tepotinib Drugs 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 230000036650 Metabolic stability Effects 0.000 description 5
- 230000002378 acidificating Effects 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000003000 nontoxic Effects 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000700 tracer Substances 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 229960000583 Acetic Acid Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N carbon bisulphide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cells Anatomy 0.000 description 4
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 3
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 210000004185 Liver Anatomy 0.000 description 3
- 206010027476 Metastasis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 3
- 229910017906 NH3H2O Inorganic materials 0.000 description 3
- 108091000081 Phosphotransferases Proteins 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M Potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 102000001253 Protein Kinases Human genes 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000000259 anti-tumor Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Substances [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- 108020004084 membrane receptors Proteins 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000003285 pharmacodynamic Effects 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrugs Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Substances [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 101700004551 BRAF Proteins 0.000 description 2
- 102100004328 BRAF Human genes 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- 102100003042 HIF1A Human genes 0.000 description 2
- 101700000053 HIF1A Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N Isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 102100013180 KDR Human genes 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108060001084 Luciferase family Proteins 0.000 description 2
- 101700067074 MAPK Proteins 0.000 description 2
- 101710041325 MAPKAPK2 Proteins 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N Manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 2
- 101710027499 Os03g0268000 Proteins 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M Sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N Suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 108091007928 VEGF receptors Proteins 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 2
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000001146 hypoxic Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- DKZQZHQHDMVGHE-UHFFFAOYSA-N methanedisulfonyl chloride Chemical compound ClS(=O)(=O)CS(Cl)(=O)=O DKZQZHQHDMVGHE-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 239000001184 potassium carbonate Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 101710024887 rl Proteins 0.000 description 2
- 150000003384 small molecules Chemical group 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- 101700045897 spk-1 Proteins 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000004434 sulfur atoms Chemical group 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- YPZMPEPLWKRVLD-PJEQPVAWSA-N (2R,3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O YPZMPEPLWKRVLD-PJEQPVAWSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- MGNZXYYWBUKAII-UHFFFAOYSA-N 1,3-Cyclohexadiene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-Naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- WCIFVXNIHUSTHF-UHFFFAOYSA-N 1-bromopropane Chemical group [CH2]CCBr WCIFVXNIHUSTHF-UHFFFAOYSA-N 0.000 description 1
- BYLAWYTWAYOBDP-UHFFFAOYSA-N 1-chlorobutane Chemical group [CH2]CCCCl BYLAWYTWAYOBDP-UHFFFAOYSA-N 0.000 description 1
- BJMSXWLXFYZHIU-UHFFFAOYSA-N 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CN1C=CC(B2OC(C)(C)C(C)(C)O2)=N1 BJMSXWLXFYZHIU-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- FGGNSZOWQBNXNV-UHFFFAOYSA-N 2-bromo-1H-pyridine-2-carbonitrile Chemical compound N#CC1(Br)NC=CC=C1 FGGNSZOWQBNXNV-UHFFFAOYSA-N 0.000 description 1
- QIPXEPRGYVAQFI-UHFFFAOYSA-N 2-bromopyridine-3-carbonitrile Chemical compound BrC1=NC=CC=C1C#N QIPXEPRGYVAQFI-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FQAWBGAIOYWONH-UHFFFAOYSA-N 3-chloroperoxybenzoic acid Chemical compound OC(=O)C1=CC=CC(OOCl)=C1 FQAWBGAIOYWONH-UHFFFAOYSA-N 0.000 description 1
- 101710042050 A43R Proteins 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 101700078950 CD44 Proteins 0.000 description 1
- 102100003735 CD44 Human genes 0.000 description 1
- 108050001278 CDC42 Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 230000035700 Clearance Rate Effects 0.000 description 1
- 229960003067 Cystine Drugs 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229940121647 EGFR inhibitors Drugs 0.000 description 1
- 102100009835 EPHB2 Human genes 0.000 description 1
- 229960001484 Edetic Acid Drugs 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229940097043 Glucuronic Acid Drugs 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940044173 Iodine-125 Drugs 0.000 description 1
- 229940045996 Isethionic Acid Drugs 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine zwitterion Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101700083887 MAPK1 Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- VRLIPUYDFBXWCH-UHFFFAOYSA-N Methylidyne radical Chemical group [CH] VRLIPUYDFBXWCH-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- RLKHFSNWQCZBDC-UHFFFAOYSA-N N-(benzenesulfonyl)-N-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 1
- 229940074355 Nitric Acid Drugs 0.000 description 1
- 101710003000 ORF1/ORF2 Proteins 0.000 description 1
- 229940116315 Oxalic Acid Drugs 0.000 description 1
- 101710018405 PTPN11 Proteins 0.000 description 1
- 102100017818 PTPN11 Human genes 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940055726 Pantothenic Acid Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229960004838 Phosphoric acid Drugs 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N Phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 101700023645 RAC1 Proteins 0.000 description 1
- 102100002253 RAC1 Human genes 0.000 description 1
- 101710023922 SEMA6A Proteins 0.000 description 1
- 102100017840 SEMA6A Human genes 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N Sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N Sulfanilic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N Tivantinib Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- AVFUHBJCUUTGCD-UHFFFAOYSA-M [Br-].[Mg+]C Chemical compound [Br-].[Mg+]C AVFUHBJCUUTGCD-UHFFFAOYSA-M 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- BIABKPAXSLKGLN-UHFFFAOYSA-N [dimethylamino(2H-triazolo[4,5-b]pyridin-7-yloxy)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=NC2=C1N=NN2 BIABKPAXSLKGLN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 102000029988 adhesion receptors Human genes 0.000 description 1
- 108010013985 adhesion receptors Proteins 0.000 description 1
- 101700028234 agl5 Proteins 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N dodecane-1-sulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulators Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N pantothenic acid Natural products OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L phosphate Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920003245 polyoctenamer Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- OFPTZWGZSRJCOT-MSPNRCMCSA-M potassium;2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2S,5R,6R)-3,3-d Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O OFPTZWGZSRJCOT-MSPNRCMCSA-M 0.000 description 1
- 230000000861 pro-apoptotic Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 108700000006 regulatory domains Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- KPZYAGQLBFUTMA-UHFFFAOYSA-K tripotassium;phosphate;trihydrate Chemical compound O.O.O.[K+].[K+].[K+].[O-]P([O-])([O-])=O KPZYAGQLBFUTMA-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000001875 tumorinhibitory Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Disclosed in the present invention is a type of pyridone compounds as c-met inhibitors, and specifically disclosed is a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof.
Description
(12) Granted patent specificaon (19) NZ (11) 753020 (13) B2
(47) aon date: 2021.12.24
(54) PYRIDONE COMPOUND AS C-MET TOR
(51) Internaonal Patent Classificaon(s):
C07D 213/00 C07D 401/00 C07D 401/14 C07D 403/14 A61K 31/505 A61K 31/435 A61K 31/4412
A61K 31/444 A61P 35/00
(22) Filing date: (73) Owner(s):
2017.10.27 FUJIAN COSUNTER PHARMACEUTICAL CO.,
LTD.
(23) Complete specificaon filing date:
2017.10.27 (74) Contact:
FB Rice Pty Ltd
(30) Internaonal Priority Data:
CN 201610954377.X 2016.10.27 (72) Inventor(s):
CHEN, Shuhui
(86) aonal Applicaon No.: LI, Gang
LI, Jian
XU, Xiongbin
(87) Internaonal Publicaon number: DING, Charles Z.
WO/2018/077227 HU, Lihong
HU, Guoping
CHI, Zhigang
WANG, Kun
(57) Abstract:
Disclosed in the present invenon is a type of pyridone compounds as c-met inhibitors, and
specifically sed is a compound as shown in formula (I) or a pharmaceucally acceptable salt
thereof.
NZ 753020 B2
Pyridone Compound as C-MET Inhibitor
Field of invention
The present invention s to a class of pyridone compounds as c-Met inhibitor,
specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable
salt thereof.
Prior arts
The c-Met encoded by proto-oncogene Met is a or tyrosine kinase with high binding
belonging to RON subgroup. It is the only known receptor for scattering factor or hepatocyte
growth factor (HGF). The c-Met protein is a disulfide-linked heterodimer composed of 50kD α
subunit and a 145kD β subunit, which can be divided into extracellular domain and intracellular
domain. The extracellular domain contains three structural domains with different functionality:
N-terminal ligand bonding domain (SEMA region) covering the entire α chain and partially β chain,
cystine enrichment domain with four conserved disulfide bonds, and globulin-like domain.
The ellular domain also consists of three regulatory domains: juxtamenbrane domain with
Tyr1003 phosphorylation site, tyrosine kinase catalytic domain with Tyr1234 and Tyr1235
orylation sites, and inal multifunctional binding domain with Tyr1349 and Tyr1356
binding tyrosine.
HGF induces phosphorylation of c-Met by binding to its ellular domain, and recruits
a variety of interstitial factors such as GAB1 (growth factor receptor binding protein-1) and GAB2
(growth factor receptor binding protein-2) in the C-terminal multifunctional , which r
attracts les such as SHP2, PI3K and others to bind here, hence activating RAS/MAPK,
KT, JAK/STAT pathways etc., thereby regulating the growth, migration, proliferation and
survival of cells. al action of the c-Met pathway would lead to tumorigenesis and
metastasis, as abnormal high expression of c-Met was found in various human malignancies such
as bladder cancer, gastric , lung cancer and breast cancer. Besides, c-Met is also associated
with tumor drug resistance to multiple kinase inhibitors.
The interaction between c-Met and various membrane receptors (crosstalk) constitutes a
complex network system. Crosstalk between c-Met and adhesion receptor CD44 amplifies the
response of signal peptide; crosstalk between c-Met and the brain protein receptor tes c-Met
level of independent ligand HGF, and then enhances the invasion effect; crosstalk between c-Met
and the pro-apoptotic or FAS accelerates sis; alks between c-Met and various
receptor tyrosine kinases such as EGFR, VEGFR regulate the activation between each other, thus
the angiogenesis process is affected. Crosstalk between c-Met and these membrane receptors
promotes tumorigenesis, metastasis and induces drug resistance.
Transcription factor HIF-1α is a major regulator of tumor cells adapting to hypoxic
environmental . VEGFR inhibitors cause tumor a in the early stage of treatment.
Under hypoxic environment, HIF-1α up-regulates c-Met level, the increase of c-Met concentration
thus promotes the tumor cells metastasis, generates regional expansion or asis of the tumors,
leads the tumors to escape from the oxygen-deficient environment and then build a cloning system
that more invasive and with stronger growing ability. Drug resistance of tumors to EGFR
inhibitors might be related to the up-regulation of ligand HGF levels. c-Met augmentation was
detected in 4% - 20% patients with non-small cell lung cancer resistant to Gefitinib and Erlotinib,
HGF p resistance to EGFR kinase inhibitors by using GAB1 to regulate PI3K/AKT and ERK
pathway. In d BRAF melanoma cell lines, researchers found that the augmentation of HGF
would resist the effect of BRAF inhibitor Ramurafenib. Thus, the crosstalk between c-Met and
membrane receptors induces resistance to kinase target y.
At present, there are a large amount of anti-tumor drugs on the market, such as ting
agent drugs, anti-metabolite drugs, anti-tumor antibiotics and immunomodulators etc., but most of
them are intolerant due to their high toxicity. With the in-depth study of tumor molecular biology,
the molecular mechanism of tumorigenesis and development has been revealed more and more
clearly, and molecular targeted therapy for a variety of malignant tumors has attracted extensive
attention. Molecular targeted drugs are highly selective and spectrum ive, they are
safer comparing to cytotoxic chemotherapeutic drugs, thus indicating a new direction for
pment in the field of cancer treatment.
There are currently two kinds of anti-tumor drugs ing at c-Met pathway: one is
monoclonal antibody against HGF or c-Met; the other is small molecule inhibitor against c-Met.
The small molecule tors that already entered clinical research or under research include PF-
2341066, EMD-1214063, XL-184 and ARQ-197 etc.
Among them, Tepotinib 14063) (WO2009006959, publication date 2009.1.15)
has the best antineoplastic activity, it has great inhibitory effect on a variety of c-Met overexpressed
tumor cells (c-Met enzyme activity IC50=3.67nM, MHCC97H cell IC50=6.2nM), which has entered
the stage of clinical research phase II.
However, although Tepotinib (EMD1214063) has a high selectivity, it has antage
of low metabolic stability and high clearance rate in vivo. Therefore, metabolically stable c-Met
inhibitors are urgently needed to sate for the deficiency.
Content of the present invention
The present invention provides a compound represented by formula (I) or a
pharmaceutically acceptable salt thereof,
R1 is selected from H or F;
R2 is selected from H or CH3;
while R2 is not H, the configuration of the carbon atom bonded to R2 is R or S;
A is ed from the group consisting of phenyl, pyridyl, pyrazolyl, isoxazolyl, isothiazolyl and
thiazolyl, each of which is optionally substituted by 1, 2 or 3 R3;
R3 is selected from CN, halogen, C(=O)NH2, or is selected from the group consisting of C1-6 alkyl,
C1-6 heteroalkyl, and C3-6 cycloalkyl, each of which is ally substituted by 1, 2 or 3 R0;
R0 is selected from F, Cl, Br, I, OH, CN, NH2, C(=O)NH2, or is selected from the group consisting
of C1-3 alkyl and C1-3 heteroalkyl, each of which is optionally substituted by 1, 2 or 3 R’;
R’ is selected from F, Cl, Br, I, CN, OH, NH2, CH3, CH3CH2, CF3, CHF2 or CH2F.
The “hetero” in the C1-3 heteroalkyl or C1-6 heteroalkyl is selected from the group consisting of -O-,
-C(=O)NR’-, -C(=O)NH-, -NR’-, and -NH-;
in any of the above cases, the number of the heteroatom or the heteroatomic group is independently
ed from 1, 2 or 3.
In some embodiments of the present invention, R0 is selected from F, Cl, Br, I, OH, CN,
NH2, C(=O)NH2, CH3, , CF3, CHF2, CH2F, NH2CH2, (NH2)2CH, CH3O, CH3CH2O,
2, CH3NH or (CH3)2N.
In some embodiments of the present invention, R1 is H.
In some embodiments of the present invention, R1 is F.
In some embodiments of the present invention, R2 is H.
In some embodiments of the present invention, R2 is CH3.
In some embodiments of the present invention, the configuration of the carbon atom
bonded to R2 is R.
In some embodiments of the present invention, the uration of the carbon atom
bonded to R2 is S.
In some embodiments of the present invention, R3 is selected from CN, halogen,
C(=O)NH2, or is selected from the group consisting of C1-3 alkyl and C1-3 heteroalkyl, each of which
is optionally substituted by 1, 2 or 3 R0.
In some embodiments of the present ion, R3 is selected from CN, F, Cl, Br, CH3,
CH3CH2, CF3, CHF2, CH2F, CH3O or C(=O)NH2.
In some embodiments of the present invention, A is ed from the group consisting of
, , , , and , each of which is optionally substituted
by 1, 2 or 3 R3.
In some embodiments of the t invention, A is selected from the group consisting of
, , , , , and .
In some embodiments of the present invention, A is selected from the group consisting of
, , , , and .
In some embodiments of the present invention, A is selected from the group consisting of
, , , , , ,
, and .
In some embodiments of the t invention, the compound above is selected from the
group consisting of
The present ion also es a ceutical composition sing a
therapeutically effective amount of the compound described above or the pharmaceutically
acceptable salt thereof, as well as a pharmaceutically acceptable carrier.
The present invention also provides a use of the compound or the pharmaceutically
acceptable salt thereof or the pharmaceutical composition described above in manufacturing a
medicament for treating tumor.
Technical effect
The present invention focused on the precise structural modification of the metabolic site,
so that the metabolic stability of the targeted compound had been y improved. Besides, a
brand new pyridone core structure was designed and synthesized to make the binding force n
the targeted compounds and the C-Met enzyme icantly enhanced, thus obtained a more
ent activity for inhibiting tumor from growing. In the meanwhile, in vivo
pharmacodynamics results showed that tumor growth rate of the mice who had been administered
the compound of the t invention was significantly lower than that of Tepotinib (EMD1214063)
at the same dose, further demonstrating that the compound of the present ion has better tumor
inhibition activity. The compound of the present invention has a longer half-life time, an extended
action time on the target, a more stable metabolic stability and a more excellent inhibitory activity.
Definition and description.
Unless otherwise indicated, the ing terms and phrases used herein are intended to
have the following meanings. A specific term or phrase should not be considered indefinite or
unclear in the absence of a particular definition, but should be understood in the conventional sense.
When a trade name appears herein, it is intended to refer to its corresponding commodity or active
ingredient thereof.
The term "pharmaceutically acceptable" is used herein in terms of those compounds,
materials, itions, and/or dosage forms, which are suitable for use in contact with human and
animal tissues within the scope of reliable l judgment, with no excessive toxicity, irritation,
allergic reaction or other ms or complications, commensurate with a reasonable benefit/risk
ratio.
The term "pharmaceutically acceptable salt" refers to a salt of the compound of the present
invention that is prepared by reacting the compound having a specific substituent of the t
invention with a vely non-toxic acid or base. When the compound of the present invention
contains a relatively acidic functional group, a base addition salt can be obtained by bringing the
neutral form of the compound into contact with a ient amount of base in a pure solution or a
suitable inert solvent. The pharmaceutically acceptable base addition salt includes a salt of sodium,
potassium, m, ammonium, organic amine or ium or similar salts. When the
compound of the present invention contains a relatively basic functional group, an acid addition salt
can be obtained by ng the neutral form of the compound into contact with a sufficient amount
of acid in a pure solution or a suitable inert solvent. Examples of the pharmaceutically acceptable
acid addition salt include an inorganic acid salt, wherein the inorganic acid includes, for example,
hloric acid, romic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid,
monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, en sulfate, hydroiodic acid,
phosphorous acid, and the like; and an organic acid salt, wherein the organic acid includes, for
e, acetic acid, propionic acid, isobutyric acid, maleic acid, c acid, benzoic acid,
ic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic
acid, p-toluenesulfonic acid, citric acid, tartaric acid, and esulfonic acid, and the like; and an
salt of amino acid (such as arginine and the like), and a salt of an organic acid such as glucuronic
acid and the like (refer to Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science
66: 1-19 (1977)). Certain specific compounds of the present invention contain both basic and
acidic functional groups and can be converted to any base or acid addition salt.
Preferably, through bringing the salt into contact with a base or an acid in a conventional
manner, then separating the parent compound, the neutral form of the compound is y
regenerated. The ence between the parent form of the compound and its various salt forms
lies in specific physical ties, such as different solubility in a polar solvent.
"Pharmaceutically acceptable salt" used herein belongs to a tive of the compound
of the present invention, wherein, the parent compound is modified by forming a salt with an acid
or a base. Examples of the pharmaceutically acceptable salt include but are not limited to an
inorganic acid or organic acid salt of a basic moiety such as amine, an alkali metal salt or an organic
salt of an acidic moiety such as carboxylic acid, and the like. The pharmaceutically able salt
includes conventional non-toxic salt or quaternary ammonium salt of the parent compound, such as
a salt formed by a non-toxic inorganic acid or an organic acid. The conventional non-toxic salt
includes but is not limited to the salt derived from an inorganic acid and an organic acid, wherein
the inorganic acid or organic acid is selected from the group consisting of 2-acetoxybenzoic acid,
2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid,
bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, ethanesulfonic acid,
fumaric acid, glucoheptose, gluconic acid, glutamic acid, glycolic acid, hydrobromic acid,
hydrochloric acid, hydroiodide, hydroxyl, hydroxynaphthalene, isethionic acid, lactic acid, lactose,
dodecyl sulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, nitric acid,
oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalactanal acid,
propionic acid, salicylic acid, stearic acid, subacetic acid, succinic acid, sulfamic acid, sulfanilic
acid, sulfuric acid, , tartaric acid and p-toluenesulfonic acid.
The pharmaceutically acceptable salt of the present invention can be prepared from the
parent nd that contains an acidic or basic moiety by conventional chemical methods.
Generally, such salt can be prepared by reacting the free acid or base form of the compound with a
iometric amount of an appropriate base or acid in water or an organic solvent or a mixture
thereof. Generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or
acetonitrile are preferred.
In addition to the salt form, the compound provided by the present invention also exists
in prodrug form. The prodrug of the compound described herein is the compound that readily
undergoes chemical change under physiological condition to be converted into the nd of the
present invention. Additionally, the prodrug can be converted to the compound of the present
invention by a chemical or biochemical method in vivo environment.
Certain compounds of the present invention can exist in an unsolvated form or a solvated
form, including a hydrated form. Generally, the solvated form is equivalent to the unsolvated form,
and both are encompassed within the scope of the present invention.
Certain compounds of the present invention can have an asymmetric carbon atom (optical
center) or a double bond. The racemate, diastereomer, geometric isomer and individual isomer are
all assed within the scope of the present invention.
Unless otherwise specified, a wedged bond and a dashed bond ( ) are used to
te the absolute configuration of a stereogenic , and are used to indicate the
relative configuration of a stereogenic center. When the compound described herein contains an
olefinic double bond or other ric asymmetric centers, E and Z geometric isomers are ed
unless otherwise specified. se, all tautomeric forms are encompassed within the scope of
the present invention.
The compound of the present invention may present in a specific geometric or
stereoisomeric form. The present invention contemplates all such compounds, including cis and
trans , (-)- and antiomer, (R)- and (S)-enantiomer, diastereoisomer, (D)-isomer, (L)-
isomer, and racemic mixture and other mixtures, for example, an enantiomer or diastereoisomer
enriched mixture, all of which are encompassed within the scope of the t ion. The
substituent such as alkyl may have an additional asymmetric carbon atom. All these isomers and
mixtures thereof are encompassed within the scope of the present invention.
lly active (R)- and (S)-isomer, or D and L isomer can be prepared using chiral
synthesis or chiral reagents or other conventional ques. If one kind of omer of n
nd of the present invention is to be obtained, the pure desired enantiomer can be obtained
by asymmetric synthesis or derivative action of chiral auxiliary followed by separating the resulting
diastereomeric mixture and cleaving the auxiliary group. Alternatively, when the molecule
contains a basic functional group (such as amino) or an acidic functional group (such as carboxyl),
the compound reacts with an appropriate optically active acid or base to form a salt of the
diastereomeric isomer which is then subjected to diastereomeric resolution through the conventional
method in the art to give the pure enantiomer. In addition, the enantiomer and the diastereoisomer
are generally isolated through tography which uses a chiral stationary phase and optionally
combines with a chemical derivative method (for example, carbamate generated from amine).
The nd of the present invention may contain an unnatural proportion of atomic
e at one or more than one atom(s) that tute the compound. For example, the compound
can be radiolabeled with a radioactive isotope, such as tritium (3H), iodine-125 (125I) or C-14 (14C).
All ic variations of the compound of the present invention, whether ctive or not, are
encompassed within the scope of the present ion.
The term "pharmaceutically acceptable carrier" refers to any agent or r medium
which is capable of delivering an effective amount of the active substance of the t invention,
does not interfere with the biological activity of the active substance and has no toxic side effect on
the host or patient. The representative carrier includes water, oil, vegetable and mineral, cream
base, lotion base, ointment base and the like. The base includes a suspending agent, a thickener, a
penetration enhancer and the like. Their formulations are well known to the skilled in the cosmetic
field or the l pharmaceutical field. The additional information about the carrier can be
referred to Remington: The Science and Practice of Pharmacy, 21st Ed, Lippincott, Williams &
Wilkins (2005), the disclosure of which is incorporated herein by reference.
For a medicament or a pharmacologically active agent, the term "effective amount" or
"therapeutically effective amount" refers to a nontoxic but sufficient amount to achieve a d
effect of the medicament or the agent. For the oral dosage form of the present invention, an
"effective amount" of the active substance in the composition refers to an amount required for
achieving a desired effect when combining with another active substance in the composition. The
effective amount varies from person to person and is determined depending on the age and general
condition of the recipient as well as the specific active substance. The appropriate effective
amount in an individual case can be determined by the skilled in the art based on routine experiment.
The term "active ient", "therapeutic agent", "active nce" or "active agent"
refers to a chemical entity which can effectively treat the target disorder, disease or ion.
"Optional" or "optionally" means that the subsequent event or condition may occur but
not requisite, that the term includes the instance in which the event or condition occurs and the
instance in which the event or condition does not occur.
The term "substituted" means one or more than one hydrogen atom(s) on a specific atom
are substituted by a tuent, including deuterium and hydrogen variants, as long as the valence
of the specific atom is normal and the substituted nd is stable. When the substituent is a
keto group (i.e. =O), it means two hydrogen atoms are substituted. Positions on an aromatic ring
cannot be substituted by a keto group. The term "optionally tuted" means an atom can be
substituted by a substituent or not, unless otherwise specified, the species and number of the
substituent may be ary as long as being chemically achievable.
When any variable (such as R) occurs in the constitution or structure of the compound
more than once, the definition of the variable at each occurrence is independent. Thus, for example,
if a group is substituted by 0-2 R, the group can be optionally substituted by up to two R, wherein
the definition of R at each ence is ndent. Moreover, a combination of the substituent
and/or the variant thereof is allowed only when the combination results in a stable compound.
When a bond of a substituent can be cross-linked to two atoms on a ring, such substituent
can be bonded to any atom on the ring. When an enumerative substituent does not indicate by
which atom it is attached to a compound included in the l chemical formula but not
specifically mentioned, such substituent can be bonded by any of its atoms. A combination of
substituents and/or variants thereof is d only when such combination can result in a stable
compound. For example, the structural unit or means that it can
be substituted at any position on cyclohexyl or cyclohexadiene.
Unless ise specified, the term "hetero" represents a atom or a heteroatom
group (e.g., an atom group containing a heteroatom), including the atom except carbon (C) and
hydrogen (H) and the atom group containing the above heteroatom, for example, including oxygen
(O), nitrogen (N), sulfur (S), silicon (Si), germanium (Ge), aluminum (Al), boron (B), -O-, -S-, =O,
=S, -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O), -S(=O)2-, and the group consisting of -C(=O)N(H)-, -
N(H)-, -C(=NH)-, -S(=O)2N(H)- and -S(=O)N(H)-, each of which is optionally substituted.
Unless otherwise specified, the term "heterohydrocarbyl" or its hyponyms (such as
heteroalkyl, heteroalkenyl, heteroalkynyl, and heteroaryl, etc.), by itself or as part of another
substituent, refers to a stable linear, branched or cyclic hydrocarbon group or any combination
thereof, which has a specified number of carbon atoms and at least one heteroatom. In some
embodiments, the term oalkyl" by itself or in combination with another term refers to a stable
linear chain, branched hydrocarbon radical or a combination thereof which has a specified number
of carbon atoms and at least one atom. In a specific embodiment, a heteroatom is selected
from B, O, N and S, n nitrogen and sulfur atoms are optionally ed and the nitrogen
atom is optionally quaternized. The atom or heteroatom group can be located at any interior
position of a heterohydrocarbyl, including the position where the hydrocarbyl attaches to the rest
part of the molecule. But the terms "alkoxy", "alkylamino" and "alkylthio" (or thioalkyl) are used
by the conventional meaning and refer to an alkyl group ted to the rest part of the molecule
via an oxygen atom, an amino or a sulfur atom respectively. Examples include, but are not limited
to, -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, H2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2,
-S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -CH2-CH=N-OCH3 and –CH=CH-N(CH3)-
CH3. Up to two consecutive heteroatoms can be t, such as, -CH2-NH-OCH3.
Unless otherwise specified, the term "alkyl" refers to a linear chain or branched saturated
hydrocarbon group, can be mono-substituted (e.g. -CH2F) or poly-substituted (e.g. -CF3), can be
monovalent (e.g. methyl), divalent (e.g. methylene) or multivalent (e.g. methenyl). Examples of
alkyl include methyl (Me), ethyl (Et), propyl (such as yl and isopropyl), butyl (such as nbutyl
, isobutyl, s-butyl, l), pentyl (such as yl, isopentyl, neopentyl) and the like.
Unless otherwise ied, cycloalkyl includes any stable cyclic or polycyclic
hydrocarbyl, and any carbon atom is saturated, can be ubstituted or poly-substituted, and can
be monovalent, divalent or multivalent. Examples of cycloalkyl include, but are not d to,
cyclopropyl, norbornanyl, [2.2.2]bicyclooctane, [4.4.0]bicyclodecanyl and the like.
Unless otherwise specified, the term "halo" or "halogen" by itself or as part of another
substituent refers to ne, chlorine, bromine or iodine atom. Furthermore, the term "haloalkyl"
is meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C1-C4)alkyl"
is meant to include, but not limited to, oromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-
bromopropyl and the like. Examples of haloalkyl include, but not limited to oromethyl,
trichloromethyl, pentafluoroethyl and hloroethyl.
The compound of the present invention can be prepared by a variety of synthetic methods
well known to the d in the art, including the following enumerative embodiment, the
embodiment formed by the following enumerative embodiment in combination with other chemical
sis s and the equivalent replacement well known to the d in the art. The
preferred embodiment includes, but is not limited to the embodiment of the present invention.
All of the solvents used in the present invention are commercially available. The present
ion employs the following abbreviations: aq represents water; HATU represents O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; EDC represents N-(3-
dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride; m-CPBA represents 3-
chloroperoxybenzoic acid; eq represents equivalent or equivalence; CDI represents carbonyl
diimidazole; DCM represents dichloromethane; PE ents petroleum ether; DIAD represents
diisopropyl azodicarboxylate; DMF represents N,N-dimethylformamide; DMSO represents
dimethyl sulfoxide; EtOAc represents ethyl acetate; EtOH represents ethanol; MeOH represents
methanol; CBz represents benzyloxycarbonyl, which is an amino protecting group; BOC ents
tert-butylcarbonyl, which is an amino protecting group; HOAc represents acetic acid; NaCNBH3
represents sodium cyanoborohydride; rt represents room temperature; O/N represents overnight;
THF represents tetrahydrofuran; Boc2O represents di-tert-butyldicarbonate; TFA ents
trifluoroacetic acid; DIPEA represents diisopropylethylamine; SOCl2 represents thionyl chloride;
CS2 represents carbon disulfide; TsOH represents p-toluenesulfonic acid; NFSI represents ro-
N-(benzenesulfonyl) benzenesulfonamide; NCS ents N-chlorosuccinimide; n-Bu4NF
represents tetrabutylammonium fluoride; iPrOH represents 2-propanol; mp represents melting point;
LDA represents lithium diisopropylamide.
Compounds are named manually or by ChemDraw® software, the commercially available
compounds use their vendor directory names.
Detailed description of the red embodiment
The following embodiments further illustrate the present invention, but by all means the
invention is not limited thereto. While the present ion has been bed in detail and with
reference to specific embodiments thereof, it will be apparent to those skilled in the art that various
changes and modifications can be made therein without departing from the spirit and scope thereof.
Embodiment 1(1-1 and 1-2)
Step A:
The solution of intermediate 7C (synthetic method see embodiment 7) (20.4 g, 50.88
mmol) and manganese dioxide (44.23 g, 508.7 mmol) in DCM (300 mL) was stirred at room
temperature for 16 hours. After the on was complete, the mixture was filtered and
concentrated to give the intermediate 1A (18.4 g) which was used directly for the next step. LCMS
(ESI) m/z: 398(M+1).
Step B:
Methylmagnesium bromide (3 M, 38.58 mL) was added into a solution of intermediate
1A (23.0 g, 57.87 mmol) in THF (200 mL) at 0℃. The solution was stirred at room ature
for 1 hour. After the reaction was complete, the mixture was quenched by saturated sodium
chloride solution (300 mL), extracted by ethyl e (200 mL*2), dried over anhydrous sodium
sulfate, filtered and concentrated to give intermediate 1B (22.76 g, yield ). LCMS (ESI)
m/z: 414(M+1). HNMR (400MHz, CHLOROFORM-d) δ =8.46 (s, H), 8.38-8.33 (m,1H), 8.26
(td, J=1.9,6.9 Hz, 1H), 7.53 - 7.44 (m, 2H), 5.02 (q, J=6.4 Hz, 1H), 4.31 - 4.12 (m, 2H), 3.95 (d,
J=6.4 Hz, 2H), 2.78 (br t, J=12.1 Hz, 2H), 2.13 (br s, 1H), 2.08 - 1.96 (m, 1H), 1.86 (br d, J=12.9
Hz, 2H), 1.58 (d, J=6.5 Hz, 3H), 1.49 (s, 9H), 1.39 - 1.29 (m, 2H).
Step C:
Diisopropylethylamine (21.34 g, 165.12 mmol) and methanesulfonyl chloride (9.12 g,
79.62 mmol) were added into a solution of intermediate 1B (22.7 g, 55.04 mmol) in DCM (300 mL)
at 0℃. The reaction solution was stirred at room temperature for 1h. After the reaction was
complete as monitored by TLC, the mixture was washed with saturated ammonium de on
(200 mL) twice, dried over ous sodium sulfate, filtered and concentrated to give the
intermediate 1C (30 g, crude product) which was used directly for the next step.
Step D:
Potassium carbonate (10.68 g, 77.30 mmol), potassium iodide (641.58 mg, 3.86 mmol)
and 5-bromofluoro-1H-pyridinone (11.13 g, 57.97 mmol) were added into a solution of
intermediate 1C (19 g, 3.86 mmol) in DMF (100 mL) at room ature. The on solution
was stirred at 90℃ for 3 hours. After the on was complete, ethyl acetate (300 mL) was added
into the solution and the solution was washed with brine (300mL) three times. The organic phase
was dried over anhydrous sodium sulfate, filtered and concentrated to give the intermediate 1D (5.8
g, yield 25.54%). HNMR (400MHz, FORM-d) δ = 8.47 (s, 2H), 8.41 - 8.32 (m, 2H),
7.55 - 7.47 (m, 1H), 7.39 (d, J=7.7 Hz, 1H), 7.15 (dd, J=2.4, 8.4 Hz, 1H), 7.11 - 7.07 (m, 1H), 6.52
(q, J=7.0 Hz, 1H), 4.31 - 4.12 (m, 2H), 4.01 - 3.93 (m, 2H), 2.87 - 2.72 (m, 2H), 2.09 - 1.98 (m, 1H),
1.89 - 1.80 (m, 5H), 1.49 (s, 9H), 1.39 - 1.30 (m, 2H).
Step E:
Under nitrogen atmosphere, intermediate 1D (2.0 g, 3.4 mmol), 4,4,5,5-tetramethyl
(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)-1,3,2-dioxaborolane (1.04 g, 4.09 mmol), acetate
potassium (668.21 mg, 6.81 mmol) and Pd(dppf)Cl2 (498.20 mg, 680.87 μmol) were dissolved in
dioxane (30 mL) at room temperature. The reaction on was stirred at 90℃ for 2 hours.
After the reaction was complete, a solution (30 mL) of intermediate 1E in dioxane was obtained and
used directly for the next step.
Step F (1F-1, 1F-2):
Under nitrogen atmosphere, a solution (30 mL) of intermediate 1E (1.92 g, 3.03 mmol) in
dioxane, sodium ate (642.30 mg, 6.06 mmol), 2-bromocyanopyridine (665.42 mg, 3.64
mmol) and Pd(dppf)Cl2 (443.43 mg, 606.0 μmol) were dissolved in e (40 mL) and water (6
mL) at room temperature. The reaction was stirred at 90℃ for 3 hours. After the reaction was
complete, the mixture was filtered and water (100 mL) was added into the filtrate and extracted with
ethyl acetate (60 mL*3). The organic phase was dried over anhydrous sodium sulfate and then
filtered and concentrated. The crude product was purified by preparative plate, and the
intermediate 1F-1 (t=2.819, 490 mg, 26.04% yield) and intermediate 1F-2 (t=3.933, 480 mg, 25.95%
yield) were isolated by SFC (column type: AS (250 mm*30 mm,10 um); mobile phase: [B:0.1%
NH3H2O EtOH]; B%: 55%-55%, 10 min; 200 minmin).
LCMS (ESI) m/z: 611 (M+1).
HNMR (intermediate 1F-1)(400MHz, METHANOL-d4) δ = 8.73 (dd, J=0.9, 5.0 Hz,
1H), 8.55 (s, 2H), 8.39 (s, 1H), 8.34 - 8.26 (m, 2H), 8.17 - 8.08 (m, 2H), 7.58 - 7.49 (m, 3H), 6.50
(q, J=7.2 Hz, 1H), 4.15 (br d, J=13.3 Hz, 2H), 4.06 (d, J=6.3 Hz, 2H), 2.84 (br s, 2H), 2.14 - 2.01
(m, 1H), 1.97 (d, J=7.3 Hz, 3H), 1.87 (br d, J=11.9 Hz, 2H), 1.48 (s, 9H), 1.35 - 1.28 (m, 2H).
HNMR mediate 1F-2)(400MHz, METHANOL-d4) δ = 8.73 (dd, J=0.8, 5.0 Hz,
1H), 8.55 (s, 2H), 8.39 (s, 1H), 8.34 - 8.26 (m, 2H), 8.16 - 8.09 (m, 2H), 7.61 - 7.49 (m, 3H), 6.50
(q, J=7.2 Hz, 1H), 4.15 (br d, J=13.2 Hz, 2H), 4.06 (d, J=6.3 Hz, 2H), 2.84 (br s, 2H), 2.12 - 2.01
(m, 1H), 1.99 - 1.95 (m, 3H), 1.87 (br d, J=10.9 Hz, 2H), 1.48 (s, 9H), 1.35 - 1.29 (m, 2H).
Step G (1G-1, 1G-2)
Trifluoroacetic acid (3 mL) was added into a solution of intermediate 1F-1 (490 mg,
786.01 μmol) in DCM (10 mL) at 0℃. The reaction solution was stirred at room temperature for
1 hour. After the reaction was complete, the mixture was evaporated to dryness to give
intermediate 1G-1 (502 mg, crude product) which was directly used for the next step. Intermediate
1G-2 (491 mg, crude product) was obtained with the same method as intermediate 1G-1.
Step H:
Formalin (326.27 mg, 4.02 mmol, 37% purity) and sodium triacetoxyborohydride (511.03
mg, 2.41 mmol) were added into a solution of intermediate 1G-1 (502.00 mg, 803.74 mmol) in
DCM (10 mL) at 0℃. The on solution was stirred at room temperature for 2 hours. After
the reaction was complete, the e was quenched with water (50 mL) and DCM (30 mL*2).
The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The crude
product obtained was purified by preparative HPLC to give the embodiment 1-1 (150 mg, 35.41%
Embodiment 1-2 (100.6 mg, 23.91% yield) was obtained with the same method as
embodiment 1-1, d from intermediate 1G-2.
Embodiment 1-1:
LCMS (ESI) m/z: 525 (M+1).
HNMR (400MHz, METHANOL-d4) δ = 8.73 (d, J=4.9 Hz, 1H), 8.56 (s, 2H), 8.49 (s,
1H), 8.39 (s, 1H), 8.34 - 8.26 (m, 2H), 8.18 - 8.09 (m, 2H), 7.61 - 7.49 (m, 3H), 6.50 (q, J=7.2 Hz,
1H), 4.13 (d, J=5.8 Hz, 2H), 3.53 (br d, J=12.4 Hz, 2H), 3.03 (br t, J=12.4 Hz, 2H), 2.87 (s, 3H),
2.27 - 2.08 (m, 3H), 1.97 (d, J=7.2 Hz, 3H), 1.81 - 1.63 (m, 2H).
Embodiment 1-2:
LCMS (ESI) m/z: 525 (M+1).
HNMR (400MHz, OL-d4) δ = 8.72 (dd, J=0.8, 5.0 Hz, 1H), 8.61 - 8.46 (m,
3H), 8.38 (s, 1H), 8.33 - 8.25 (m, 2H), 8.16 - 8.08 (m, 2H), 7.58 - 7.47 (m, 3H), 6.49 (q, J=7.1 Hz,
1H), 4.12 (d, J=5.9 Hz, 2H), 3.50 (br d, J=12.2 Hz, 2H), 3.05 - 2.93 (m, 2H), 2.83 (s, 3H), 2.22 -
2.06 (m, 3H), 1.96 (d, J=7.2 Hz, 3H), 1.80 - 1.62 (m, 2H).
Embodiment 2(2-1 and 2-2)
Step A:
Under nitrogen atmosphere, intermediate 1D (1.0 g*2, 1.70 mmol), 3-methyl(4,4,5,5-
tetramethyl-1,3,2-dioxaborolaneyl)isothiazole (1.15 g, 5.10 mmol), ium phosphate (1 M,
3.4 mL) and 1,1-(tert-butylphosphino)ferrocene palladium ride (110.80 mg, 170.00 μmol)
were dissolved in THF (10 mL) at room temperature. The reaction solution was stirred at 70℃
for 16 hours. The reaction solution was then filtered and water (50 mL) was added into. The
e was extracted by ethyl acetate (30 mL*3). The organic phase was then dried over
anhydrous sodium sulfate, filtered and concentrated. The crude product was then purified by
preparative HPLC. The intermediate 2A-1 (t=2.529, 560 mg, 24.28% yield) and intermediate 2A-
2 (t=3.494, 500 mg, 27.19% yield) were isolated by SFC ( column type: AS (250 mm*30 mm,10
um); mobile phase: [B:0.1% NH3H2O EtOH]; B%: 35%-35%, 7.2 min; 200 minmin).
LCMS (ESI) m/z: 605 (M+1)
HNMR (intermediate 400MHz, METHANOL-d4) δ = 8.61 - 8.50 (m, 2H), 8.41
- 8.26 (m, 2H), 7.76 (d, J=2.1 Hz, 1H), 7.70 (dd, J=2.1, 10.0 Hz, 1H), 7.57 - 7.50 (m, 2H), 7.29 (s,
1H), 6.45 (q, J=7.1 Hz, 1H), 4.16 (br d, J=13.3 Hz, 2H), 4.07 (d, J=6.1 Hz, 2H), 2.85 (br s, 2H),
2.45 (s, 3H), 2.08 (br s, 1H), 1.96 - 1.84 (m, 5H), 1.48 (s, 9H), 1.37 - 1.29 (m, 2H).
HNMR (intermediate 2A-2) (400MHz, METHANOL-d4) δ = 8.59 - 8.53 (m, 2H),
8.41 - 8.27 (m, 2H), 7.76 (s, 1H), 7.73 - 7.66 (m, 1H), 7.58 - 7.49 (m, 2H), 7.28 (d, J=2.8 Hz, 1H),
6.45 (q, J=6.9 Hz, 1H), 4.16 (br d, J=13.6 Hz, 2H), 4.06 (dd, J=3.9, 6.1 Hz, 2H), 2.94 - 2.78 (m,
2H), 2.44 (d, J=2.1 Hz, 3H), 2.07 (td, J=3.7, 9.6 Hz, 1H), 1.96 - 1.84 (m, 5H), 1.48 (s, 9H), 1.36 -
1.27 (m, 2H).
Step B: intermediate 2B-1 and intermediate 2B-2 were prepared ing to the
preparation method of intermediate 1G-1.
Step C: embodiment 2-1 and 2-2 were prepared according to the preparation method of
embodiment 1.
Embodiment 2-1:
LCMS (ESI) m/z: 520 (M+1).
HNMR (400MHz, METHANOL-d4) δ = 8.73 (s, 2H), 8.35 (s, 1H), 8.29 (d, J=7.2 Hz,
1H), 7.86 - 7.81 (m, 1H), 7.72 (dd, J=2.3, 10.0 Hz, 1H), 7.64 - 7.58 (m, 2H), 7.36 (s, 1H), 6.45 (q,
J=7.1 Hz, 1H), 4.21 (d, J=5.9 Hz, 2H), 3.63 (br d, J=12.4 Hz, 2H), 3.15 (br t, J=11.9 Hz, 2H), 2.92
(s, 3H), 2.47 (s, 3H), 2.33 - 2.06 (m, 3H), 1.99 (d, J=7.2 Hz, 3H), 1.86 - 1.73 (m, 2H).
Embodiment 2-2:
LCMS (ESI) m/z: 520 (M+1).
HNMR z, METHANOL-d4) δ = 8.75 (s, 2H), 8.37 (s, 1H), 8.28 (d, J=7.2 Hz,
1H), 7.88 - 7.81 (m, 1H), 7.70 (dd, J=2.3, 10.0 Hz, 1H), 7.65 - 7.56 (m, 2H), 7.34 (s, 1H), 6.42 (q,
J=7.1 Hz, 1H), 4.20 (d, J=5.9 Hz, 2H), 3.62 (br d, J=12.4 Hz, 2H), 3.12 (br t, J=11.9 Hz, 2H), 2.91
(s, 3H), 2.45 (s, 3H), 2.33 - 2.08 (m, 3H), 1.96 (d, J=7.2 Hz, 3H), 1.87 - 1.70 (m, 2H).
Embodiment 3
Step A:
Intermediate 3D was prepared according to the preparation method of intermediate 1D.
Step B:
Intermediate 3E was prepared according to the preparation method of intermediate 1F.
The intermediate 3E-1 (t=2.805, 33 mg, 33.0% yield) and intermediate 3E-2 (t=3.255, 33 mg, 33%
yield) were isolated by SFC (column type: AS (250 mm*30 mm, 10 um); mobile phase: [B: 0.1%
NH3H2O EtOH]; B%: 40%-40%, 5 min; 80 ). LCMS (ESI) m/z: 588 (M+1).
Step C:
ediate 3F-1 (580 mg, crude t) and 3F-2 (520 mg, crude product) were
prepared according to the preparation method of intermediate 1G.
Step D:
Embodiment 3-1 and 3-2 were prepared according to the preparation method of
embodiment 1.
Embodiment 3-1:
LCMS (ESI) m/z: 502 (M+1).
HNMR (400MHz, METHANOL-d4) δ = 8.62 - 8.49 (m, 3H), 8.36 (s, 1H), 8.31 (br d,
J=6.8 Hz, 1H), 7.91 (s, 1H), 7.77 (br d, J=9.4 Hz, 1H), 7.57 - 7.49 (m, 2H), 7.26 (s, 1H), 6.71 (d,
J=9.4 Hz, 1H), 6.42 (q, J=6.6 Hz, 1H), 4.13 (br d, J=5.1 Hz, 2H), 3.50 (br d, J=11.9 Hz, 2H), 2.97
(br t, J=12.2 Hz, 2H), 2.83 (s, 3H), 2.44 (s, 3H), 2.24 - 2.06 (m, 3H), 1.91 (br d, J=7.1 Hz, 3H), 1.80
- 1.61 (m, 2H).
Embodiment 3-2:
LCMS (ESI) m/z: 502 (M+1).
HNMR (400MHz, METHANOL-d4) δ = 8.56 (s, 2H), 8.49 (br s, 1H), 8.36 (s, 1H), 8.30
(br d, J=6.7 Hz, 1H), 7.91 (d, J=2.4 Hz, 1H), 7.77 (dd, J=2.4, 9.4 Hz, 1H), 7.56 - 7.49 (m, 2H), 7.26
(s, 1H), 6.70 (d, J=9.4 Hz, 1H), 6.41 (q, J=7.1 Hz, 1H), 4.13 (d, J=5.7 Hz, 2H), 3.54 (br d, J=12.3
Hz, 2H), 3.05 (br t, J=11.9 Hz, 2H), 2.87 (s, 3H), 2.44 (s, 3H), 2.21 - 2.08 (m, 3H), 1.91 (d, J=7.1
Hz, 3H), 1.79 - 1.67 (m, 2H).
Embodiment 4
Step A:
Intermediate 4A was prepared according to the ation method of intermediate 1D.
Step B:
Intermediate 4B was prepared according to the preparation method of intermediate 1E.
Step C:
Intermediate 4C was prepared according to the preparation method of intermediate 1F.
Step D:
Intermediate 4D was prepared according to the ation method of intermediate 1G.
Step E:
Embodiment 4 was prepared according to the preparation method of embodiment 1.
LCMS (ESI) m/z: 510 (M+1). HNMR (400MHz, METHANOL-d4) δ = 8.59 - 8.47 (m, 3H), 8.37
(s, 1H), 8.32 - 8.24 (m, 1H), 8.17 (d, J=2.5 Hz, 1H), 7.95 (dd, J=2.0, 7.3 Hz, 1H), 7.85 - 7.73 (m,
2H), 7.51 - 7.46 (m, 2H), 7.41 (dd, J=8.6, 10.5 Hz, 1H), 6.70 (d, J=9.5 Hz, 1H), 5.37 (s, 2H), 4.12
(d, J=5.8 Hz, 2H), 3.52 (br d, J=12.8 Hz, 2H), 3.08 - 2.96 (m, 2H), 2.85 (s, 3H), 2.26 - 2.09 (m, 3H),
1.79 - 1.63 (m, 2H).
Embodiment 5
Step A:
Intermediate 5A was prepared ing to the preparation method of intermediate 1D.
Step B:
Intermediate 5B was prepared according to the ation method of intermediate 1F.
Step C:
Intermediate 5C was prepared according to the preparation method of intermediate 1G.
Step D:
Embodiment 5 was prepared according to the preparation method of Embodiment 1.
LCMS (ESI) m/z: 506 (M+1). HNMR (400MHz, METHANOL-d4) δ = 8.58 - 8.49 (m, 3H), 8.37
- 8.26 (m, 2H), 8.16 (dd, J=1.3, 2.1 Hz, 1H), 7.74 (dd, J=2.2, 10.2 Hz, 1H), 7.50 (d, J=5.3 Hz, 2H),
7.34 (s, 1H), 5.40 (s, 2H), 4.12 (d, J=5.8 Hz, 2H), 3.51 (br d, J=12.4 Hz, 2H), 3.06 - 2.94 (m, 2H),
2.84 (s, 3H), 2.47 (s, 3H), 2.23 - 2.07 (m, 3H), 1.80 - 1.62 (m, 2H).
Emobodiment 6
Step A:
Intermediate 6A was prepared according to the preparation method of intermediate 1E.
Step B:
Intermediate 6B was prepared ing to the preparation method of intermediate 1F.
Step C:
Intermediate 6C was prepared according to the preparation method of intermediate 1G.
Step D:
Embodiment 6 was prepared according to the preparation method of Embodiment 1.
LCMS (ESI) m/z: 493 (M+1). HNMR (400MHz, OL-d4) δ = 8.75 (d, J=5.0 Hz, 1H),
8.69 (d, J=2.4 Hz, 1H), 8.58 - 8.43 (m, 3H), 8.34 (s, 1H), 8.30 - 8.22 (m, 2H), 8.13 (s, 1H), 7.55 (dd,
J=1.1, 5.0 Hz, 1H), 7.51 - 7.44 (m, 2H), 6.71 (d, J=9.5 Hz, 1H), 5.39 (s, 2H), 4.10 (d, J=5.9 Hz, 2H),
3.54 (br d, J=12.0 Hz, 2H), 3.04 (br t, J=12.0 Hz, 2H), 2.87 (s, 3H), 2.23 - 2.07 (m, 3H), 1.79 - 1.65
(m, 2H).
Embodiment 7
Step A:
Under nitrogen here, methane disulfonyl chloride (45.15 g, 394.15 mmol) was
added dropwise into a solution of tert-butyl(hydroxymethyl)piperidinecarbomate (68.00 g,
315.85 mmol) and diisopropylethylamine (81.64 g, 631.71 mmol) in dichloromethane (800 mL)
while stirring. After the dropwise on was te, the reaction solution was stirred at 25℃
for 2 hours. Thin layer chromatography was used to ensure the reaction was complete. The
reaction solution was washed with saturated ammonium chloride solution (500 mL*2) and brine
(300 mL *2) and dried over anhydrous sodium sulfate, filtered and concentrated to give ediate
7A (red oily liquid, 95.00 g, 100% yield) which was used directly for the next step without further
purification.
Step B
Under nitrogen atmosphere, potassium carbonate (74.12 g, 536.28 mmol) was added into
a solution of intermediate 7A (94.40 g, 321.77 mmol) and ropyrimidinol (35.00 g, 268.14
mmol) in DMF (1.00 L). The reaction solution was left at 80℃ for 16 hours, and thin layer
chromatography was used to detect the completion of the reaction. Then the reaction solution was
cooled to room temperature and concentrated, then water (500 mL) was added into the e and
extracted with ethyl acetate (300 mL*3). The organic phase was washed with brine (400 mL*2) and
dried over anhydrous sodium sulfate, then filtered and concentrated. Then the residue was purified
by column chromatography to give the intermediate 7B (pale yellow solid, 84.00 g, 95.05% yield).
LCMS (ESI) m/z: 327.7 (M+1). 1HNMR (400 MHz, DMSO-d6) δ ppm 1.08 - 1.25 (m, 2 H) 1.40
(s, 9 H) 1.69 - 1.78 (m, 2 H) 1.88 - 2.03 (m, 1 H) 2.58 - 2.88 (m, 2 H) 3.89 - 4.05 (m, 4 H) 8.50 -
8.57 (m, 2 H)
Step C:
Under nitrogen atmosphere, a mixed solution of ediate 7B (84.00 g, 254.85 mmol),
droxymethyl)phenyl]boronic acid (42.60 g, 280.34 mmol), Pd(PPh3)2Cl2 (17.89 g, 25.49
mmol) and potassium carbonate (70.45 g, 509.71 mmol) in 1.4-dioxane (1.00 L) and water 0
mL) was stirred at 80℃ for 16 hours. Then the reaction solution was cooled to room temperature
then filtered, followed by extraction with romethane (500 mL*3), then the organic layers were
combined together, washed with brine (500 mL *2) and dried over anhydrous sodium sulfate, then
filtered and concentrated. The residue was recrystallized with methanol to give intermediate 7C
(white solid, 77.60 g, 76.22% yield). LCMS (ESI) m/z: 400.1 (M+1). 1HNMR (400 MHz,
DMSO-d6) δ ppm 1.14 - 1.31 (m, 2 H) 1.45 (s, 9 H) 1.75 - 1.87 (m, 2 H) 1.95 - 2.10 (m, 1 H) 2.66
- 2.93 (m, 2 H) 3.94 - 4.22 (m, 4 H) 4.63 (d, J=5.62 Hz, 2 H) 5.34 (t, J=5.81 Hz, 1 H) 7.41 - 7.54
(m, 2 H) 8.21 (d, J=7.46 Hz, 1 H) 8.35 (s, 1 H) 8.68 (s, 2 H)
Step D:
Under nitrogen atmosphere, methane disulfonyl chloride (3.44 g, 30.04 mmol) was added
dropwise into a solution of intermediate 7C (10.00 g, 25.03 mmol) and diisopropylethylamine (6.47
g, 50.06 mmol) in dichloromethane (100.00 mL) while stirring. After the addition was te,
the reaction solution was stirred at 25℃ for 2 hours. The thin layer chromatography was used to
detect the completion of the reaction. The reaction solution was washed with saturated ammonium
chloride solution (500 mL*2) and brine (300 mL*2), dried over anhydrous sodium de, filtered
and concentrated to give intermediate 7D (gray solid, 14.00 g, 100% yield) which was used directly
for the next step without further purification. LCMS (ESI) m/z: 478.1 (M+1).
Step E:
Under nitrogen atmosphere, ium carbonate (6.95 g, 50.26 mmol) was added into a
on of intermediate 7D (12.00 g, 25.13 mmol) and 5-bromofluoroH-pyridinone (5.79
g, 30.16 mmol) in DMF (100.00 mL) at 25℃. The reaction on was left at 90℃ for 3 hours,
then the reaction was complete as monitored by thin layer chromatography. Then the on
solution was cooled to room temperature and concentrated. The residue was washed by water (100
mL), extracted with ethyl acetate (100 mL *3) and then the organic phase was washed by brine (200
mL*2) and dried over anhydrous sodium sulfate, then filtered and concentrated. The residue was
purified by column chromatography to give intermediate 7E (yellow solid, 9.60 g 66.62% .
LCMS (ESI) m/z: 574.9 (M+1). 1HNMR (400 MHz, DMSO-d6) δ ppm 1.09 - 1.27 (m, 2 H) 1.41
(s, 9 H) 1.77 (br d, J=11.13 Hz, 2 H) 1.90 - 2.10 (m, 1 H) 2.62 - 2.91 (m, 2 H) 3.87 - 4.14 (m, 4 H)
.16 - 5.30 (m, 2 H) 7.39 - 7.52 (m, 2 H) 7.76 (dd, J=9.66, 2.45 Hz, 1 H) 8.14 - 8.19 (m, 1 H) 8.24
(d, J=7.58 Hz, 1 H) 8.28 (s, 1 H) 8.65 (s, 2 H)
Step F:
Under nitrogen atmosphere, a mixed solution of intermediate 7F (200.00 mg, 348.77
mmol), 5-tetramethyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolaneyl)-1,3,2-dioxaborolane
(92.99 mg, 366.21 mmol), Pd(dppf)Cl2 (25.52 mg, 34.88 μmol) and potassium acetate (102.68
mg ,1.05 mmol) in 1,4-dioxane (10.00 mL) was stirred at 70℃ for 2 hours to give a on of
intermediate 7F in dioxane, which was used directly for the next step without further purification.
Step G:
Under nitrogen atmosphere, a mixed solution of intermediate 7F in dioxane solution
0 mg, 338.43 μmol), 2-bromopyridincarbonitrile (185.81 mg, 1.02 mmol), Pd(dppf)Cl2-
CH2Cl2 (55.28 mg, 67.69 μmol) and potassium carbonate (93.55 mg, 676.86 μmol) in 1,4-dioxane
(10.00 mL) and water (2.00 mL) was stirred at 80℃ for 3 hours. The reaction on was then
cooled to room temperature, filtered and concentrated. The residue was dissolved by adding water
(50 mL) and extracted with ethyl acetate (30 mL *3). Then organic phases were combined, washed
with brine (30 ml *2), dried over anhydrous sodium sulfate, followed by filtration and concentration.
The residue was purified by preparative thin layer chromatography to give ediate 7G (yellow
solid, 50.00 mg, 24.76% yield). LCMS (ESI) m/z: 619.2 (M+23).
Step H:
Under nitrogen atmosphere, trifluoroacetic acid (4.62 g, 40.52 mmol, 3.00 mL) was added
into a solution of intermediate 7G (50.00 mg, 83.80 μmol) in dichloromethane (10.00 mL) at 0℃.
The reaction solution was stirred at 25℃ for 1 hour, then concentrated to obtain intermediate 7H
(brownish black oily liquid, 60.00 mg, 100% yield, trifluoroacetate), which was used for the next
step ly without further purification. LCMS (ESI) m/z: 497.2 (M+1).
Step I:
Under nitrogen here, formaldehyde (40.87 mg, 503.50 μmol, 37.50 μL, 37%
aqueous on) and sodium triacetoxyborohydride (64.03 mg, 302.10 μmol) were added into a
solution of intermediate 7H (50.00 mg, 100.70 μmol) in dichloromethane (5.00 mL) at 0℃. The
reaction solution was left at 25℃ for 16 hours, then concentrated. The residue was purified by
preparative HPLC to obtain ment 7 (21.70 mg, 38.48% yield, formate). LCMS (ESI) m/z:
511.1 (M+1). 1HNMR(400 MHz, DMSO-d6) δ ppm 1.27 - 1.43 (m, 2 H) 1.77 (br d, J=9.78 Hz,
3 H) 1.99 (br t, J=11.43 Hz, 2 H) 2.22 (s, 3 H) 2.85 (br d, J=11.37 Hz, 2 H) 4.05 (d, J=5.99 Hz, 2 H)
.39 (s, 2 H) 7.50 (d, J=5.01 Hz, 2 H) 7.75 (dd, J=5.01, 1.22 Hz, 1 H) 8.18 - 8.26 (m, 2 H) 8.28 (s,
1 H) 8.33 (s, 1 H) 8.40 (s, 1 H) 8.64 (s, 2 H) 8.78 (d, J=1.34 Hz, 1 H) 8.82 (d, J=5.01 Hz, 1 H)
Embodiment 8(8-1 and 8-2)
Step A:
Under nitrogen atmosphere, a solution of intermediate 1D (1.50 g, 2.55 μmol), tributyl(1-
ethylene)tin (1.14 g, 3.16 mmol, 1.07 mL) and Pd(dppf)Cl 2 (358.43 mg, 510.66 μmol) in
toluene (10.00 mL) was stirred at 100℃ for 3 hours. Hydrochloric acid (10.21 mL, 1 N aqueous
solution) was added into the reaction solution after the solution was cooled to room temperature and
then the solution was stirred at 25℃ for 1 hour, filtered and concentrated. The residue was purified
by column chromatography to give ediate 8A (yellow oily liquid, 1.13 g, 80.48% yield).
LCMS (ESI) m/z: 573.1 (M+23). 1HNMR (400 MHz, CHLOROFORM-d) δ ppm 1.50 (s, 9 H)
1.89 (d, J=7.03 Hz, 6 H) 1.98 - 2.10 (m, 2 H) 2.31 (s, 3 H) 2.72 - 2.86 (m, 2 H) 3.98 (d, J=6.27 Hz,
2 H) 4.12 - 4.31 (m, 2 H) 6.54 (q, J=7.28 Hz, 1 H) 7.42 (br d, J=7.65 Hz, 1 H) 7.61 (dd, J=9.66, 2.26
Hz, 1 H) 7.65 - 7.74 (m, 1 H) 7.84 (d, J=1.38 Hz, 1 H) 8.38 (d, J=7.78 Hz, 1 H) 8.42 (s, 1 H) 8.47
(s, 2 H)
Step B:
Under en atmosphere, a solution of intermediate 8A (1.13 g, 2.05 mmol) in 1,1-
dimethoxy-N,N-dimethyl-ethane (5.00 mL) was stirred at 120℃ for 3 hours. Then the reaction
solution was cooled to room temperature and trated to dryness to obtain the intermediate 8B
(brownish black oily liquid, 1.27 g, 100% yield), which was used directly for next step without
further purification. LCMS (ESI) m/z: 620.1 (M+1).
Step C:
Under en atmosphere, hydroxylamine (213.61 mg, 3.08 mmol, hydrochloride salt)
was added into a solution of intermediate 8B (1.27 g, 2.05 mmol) in ethanol (20.00 mL). The
mixture was left at 80℃ for 16 hours, then concentrated. The e was purified by preparative
HPLC, the racemates were separated by preparative SFC (column : AS(250 mm*30 mm,10 um);
phase mobile:[0.1% NH3-H2O EtOH];B%:0%-55%,5.2 min;150 minmin)to intermediate
8C-1 (white solid, 380.00 mg, 31.44%yield, 100% ee value, Rt=2.431 min) and intermediate 8C-2
(white solid, 350.00mg, 38.95%yield, 100% ee value, Rt=3.299 min). LCMS (ESI) m/z: 590.4
(M+1). 1HNMR(intermediate 8C-1) (400 MHz, CHLOROFORM-d) δ ppm 1.31 - 1.38 (m, 2
H) 1.50 (s, 9 H) 1.82 - 1.94 (m, 5 H) 1.97 - 2.12 (m, 1 H) 2.29 (s, 3 H) 2.79 (br t, J=12.23 Hz, 2 H)
3.98 (d, J=6.36 Hz, 2 H) 4.21 (br s, 2 H) 6.06 (s, 1 H) 6.59 (d, J=6.97 Hz, 1 H) 7.33 (dd, J=9.41,
2.20 Hz, 1 H) 7.40 - 7.46 (m, 1 H) 7.48 - 7.55 (m, 1 H) 7.56 - 7.62 (m, 1 H) 8.36 (d, J=7.70 Hz, 1
H) 8.43 (s, 1 H) 8.47 (s, 2 H ).
1HNMR(intermediate 8C-2) (400 MHz, CHLOROFORM-d) δ ppm 1.30 - 1.37 (m, 2
H) 1.49 (s, 9 H) 1.81 - 1.94 (m, 5 H) 1.96 - 2.10 (m, 1 H) 2.29 (s, 3 H) 2.79 (br t, J=12.10 Hz, 2 H)
3.98 (d, J=6.24 Hz, 2 H) 4.20 (br s, 2 H) 6.06 (s, 1 H) 6.59 (q, J=7.05 Hz, 1 H) 7.33 (dd, J=9.29,
2.20 Hz, 1 H) 7.41 - 7.46 (m, 1 H) 7.48 - 7.54 (m, 1 H) 7.59 (d, J=1.59 Hz, 1 H) 8.36 (d, J=7.82 Hz,
1 H) 8.42 (s, 1 H) 8.47 (s, 2 H)
Step D:
Intermediates 8D-1, 8D-2 were prepared according to the ation method of
intermediate 1G.
Step E:
Embodiments 8-1, 8-2 were prepared according to the preparation method of embodiment
ment 8-1:
LCMS (ESI) m/z: 504.1 (M+1).
1HNMR (400 MHz, DMSO-d6) δ ppm 1.54 - 1.72 (m, 2 H) 1.85 - 2.13 (m, 6 H) 2.24 (s,
3 H) 2.69 - 2.80 (m, 3 H) 2.86 - 3.16 (m, 2 H) 3.19 - 3.52 (m, 2 H) 4.09 (d, J=6.27 Hz, 2 H) 6.29 (q,
J=7.07 Hz, 1 H) 6.78 (s, 1 H) 7.47 - 7.60 (m, 2 H) 7.92 (dd, J=10.42, 2.13 Hz, 1 H) 8.08 (s, 1 H)
8.21 - 8.35 (m, 2 H) 8.62 - 8.75 (m, 2 H) 10.37 - 10.80 (m, 1 H)
Embodiments 8-2
LCMS (ESI) m/z: 504.1 (M+1).
1HNMR (400 MHz, 6) δ ppm 1.57 - 1.74 (m, 2 H) 1.81 - 2.12 (m, 6 H) 2.23 (s,
3 H) 2.62 - 2.79 (m, 3 H) 2.86 - 3.05 (m, 2 H) 3.41 (br d, J=11.92 Hz, 2 H) 4.09 (d, J=6.27 Hz, 2 H)
6.29 (q, J=6.99 Hz, 1 H) 6.79 (s, 1 H) 7.53 (d, J=5.02 Hz, 2 H) 7.92 (dd, J=10.48, 2.07 Hz, 1 H)
8.08 (s, 1 H) 8.20 - 8.34 (m, 2 H) 8.61 - 8.73 (m, 2 H) 10.75 (br s, 1 H)
Embodiment 9
Step A:
Under nitrogen here, a mixture of intermediate 3D (1.00 g, 1.76 mmol), 4,4,5,5-
tetramethyl-(4,4,5,5-tetramethyl-1,3,2-dioxaborolaneyl)-1,3,2-dioxaborolane 8 mg, 1.85
mmol), Pd(dppf)Cl2 (128.78 mg, 176.00 μmol) and potassium acetate (518.17 mg, 5.28 mmol) in
1,4-dioxane (15.00 mL) was stirred at 80℃ for 2 hours, then intermediate 9A in dioxane was
ed and was used directly for the next step without further treatment.
Step B:
Under nitrogen atmosphere, a mixture of intermediate 9A (1.09 g, 1.77 mmol) in dioxane,
2-bromopyridinecarbonitrile (485.89 mg, 2.66 mmol), Pd(dppf)Cl2·CH2Cl2 (289.09 mg, 354.00
μmol) and ium carbonate (489.26 mg, 3.54 mmol) in 1,4-dioxane (20.00 mL) and water (4.00
mL) in solution was stirred at 80℃ for 3 hours. Then the reaction solution was cooled to room
temperature, filtered and concentrated. The residue was purified by preparative thin layer
chromatography, the racemates was separated by preparative SFC (column: AS(250 mm*30 mm,10
um); phase mobile: [0.1% NH3-H2O EtOH]; B%: 55%-55%, 8.2 min; 100 minmin) to intermediate
9B-1 (yellow oily , 200.00 mg, 100% ee value, 19.06% yield, Rt=2.973 min) and intermediate
9B-2 (yellow oily , 200.00 mg, 100% ee value, 19.06% yield, Rt=3.605min). LCMS (ESI)
m/z: 593.1 (M+1).
Step C
Intermediate 9C-1, 9C-2 was prepared according to the preparation method of 1G.
Step D:
Embodiment 9-1, 9-2 was prepared according to the preparation method of embodiment
Embodiment 9-1:
LCMS (ESI) m/z: 507.1 (M+1). 1HNMR (400 MHz, DMSO-d6) δ ppm 1.29 - 1.45 (m,
2 H) 1.80 (br d, J=10.54 Hz, 3 H) 1.88 (d, J=7.28 Hz, 3 H) 2.14 (br t, J=11.17 Hz, 2 H) 2.30 (s, 3 H)
2.94 (br d, J=11.29 Hz, 2 H) 4.05 (d, J=6.02 Hz, 2 H) 6.32 (d, J=7.15 Hz, 1 H) 6.62 (d, J=9.66 Hz,
1 H) 7.46 - 7.55 (m, 2 H) 7.69 (dd, J=5.02, 1.25 Hz, 1 H) 8.19 - 8.26 (m, 3 H) 8.27 (s, 1 H) 8.43 (t,
J=1.07 Hz, 1 H) 8.49 (d, J=2.38 Hz, 1 H) 8.64 (s, 2 H) 8.77 (dd, J=5.02, 0.88 Hz, 1 H)
Embodiment 9-2
LCMS (ESI) m/z: 507.1 (M+1). 1HNMR (400 MHz, DMSO-d6) δ ppm 1.27 - 1.46 (m,
2 H) 1.81 (br d, J=10.54 Hz, 3 H) 1.89 (d, J=7.28 Hz, 3 H) 2.17 (br t, J=11.17 Hz, 2 H) 2.31 (s, 3 H)
2.96 (br d, 9 Hz, 2 H) 4.09 (d, J=6.02 Hz, 2 H) 6.35 (d, J=7.15 Hz, 1 H) 6.65 (d, J=9.66 Hz,
1 H) 7.42 - 7.57 (m, 2 H) 7.66 (dd, J=5.02, 1.25 Hz, 1 H) 8.21 - 8.27 (m, 3 H) 8.29 (s, 1 H) 8.45 (t,
J=1.07 Hz, 1 H) 8.51 (d, J=2.38 Hz, 1 H) 8.67 (s, 2 H) 8.79 (dd, J=5.02, 0.88 Hz, 1 H)
Embodiment 10
Step A:
Under nitrogen atmosphere, a mixture of intermediate 4A (200.00 mg, 346.53 μmol), 1-
methyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolaneyl)pyrazole 5 mg, 519.80 μmol),
f)Cl2 (25.36 mg, 34.65 μmol) and sodium carbonate 9 mg, 1.04 mmol) in 1,4-dioxane
(10.00 mL) was stirred at 80℃ for 2 hours, then the reaction solution was cooled to room
temperature, filtered and concentrated. The residue was dissolved by adding water (60 mL) and
then extracted with ethyl acetate (50 mL*3). Then organic phases were combined and washed
with brine (80 mL *2), and dried over ous sodium sulfate, filtered and concentrated. The
residue was purified by preparative thin layer chromatography to give intermediate 10B (yellow
oily liquid, 200.00 mg, 95.45% yield). LCMS (ESI) m/z: 557.3 (M+1).
Step B:
Intermediate 10C was prepared according to the preparation method of intermediate 1G.
Step C:
Embodiment 10 was prepared according to the preparation method of embodiment 1.
LCMS (ESI) m/z: 471.2 (M+1). 1HNMR (400 MHz, METHANOL-d4): 1.63 - 1.80 (m, 2 H) 2.09
- 2.25 (m, 3 H) 2.88 (s, 3 H) 3.05 (t, J=12.17 Hz, 2 H) 3.55 (d, J=12.67 Hz, 2 H) 3.91 (s, 3 H) 4.12
(d, J=5.90 Hz, 2 H) 5.34 (s, 2 H) 6.67 (d, J=9.41 Hz, 1 H) 7.42 - 7.51 (m, 2 H) 7.75 (s, 1 H) 7.81
(dd, , 2.57 Hz, 1 H) 7.88 (s, 1 H) 8.05 (d, J=2.38 Hz, 1 H) 8.25 - 8.29 (m, 1 H) 8.33 (s, 1 H)
8.47 (s, 1 H) 8.55 (s, 2 H).
Embodiment 11
Step A:
Under nitrogen atmosphere, a solution of sodium nitrite (2.52 g, 36.54 mmol) in water (50
mL) was added dropwise into a mixed solution of 3-methyisothiazolamine (5.00 g, 33.19 mmol,
hydrochloride salt) in water (14.00 mL) and ic acid (10.00 mL, 98% purity) at 0℃. The
reaction solution was stirred at 0℃ for 1 hour, then a solution of potassium iodide (6.06 g, 36.51
mmol) in water (35 mL) was added and the solution was left at 80℃ for 1 hour for reaction. The
reaction solution was cooled to room temperature, diluted with water (100 mL) and extracted with
dichloromethane (50 mL*2). Then the organic phases were combined and washed with brine (25
mL*2), dried over anhydrous sodium sulfate, ed and concentrated. The residue was purified
by column chromatography to give ediate 11A (yellow solid, 4.00 g, 53.55% yield). LCMS
(ESI) m/z: 225.9 (M+1). 1HNMR (400 MHz, CHLOROFORM-d) δ ppm 2.39 - 2.48 (m, 3 H)
7.04 - 7.13 (m, 1 H).
Step B:
Under en atmosphere, isopropylamagnesium chloride-lithium de complex
(3.66 mL, 1.3 M ydrofuran solution) was added dropwise into a solution of intermediate 11A
(1.00 g, 4.44 mmol) and 2-isopropoxy-4,4,5,5-1,3,2-dioxaborolane (850 mg, 4.57 mmol) in
tetrahydrofuran (5.00 mL) at -25℃. The reaction solution was stirred at -25℃ for 0.5 hour.
After the reaction, the solution was quenched by dripping into a solution of acetic acid (0.24 mL) in
ydrofuran (0.67 mL), then petroleum ether (48 mL) and tert-butyl methyl ether (24 mL) were
added into the reaction solution. After filtration, tert-butyl methyl ether (32 mL) was added into
filtrate, then the filtrate was again filtered and concentrated to give intermediate 11B (yellow oily
, 512 mg, 51.22% yield)which was used for the next step directly without r purification.
1HNMR (400 MHz, CHLOROFORM-d) δ ppm 1.28 (s, 12 H) 2.46 - 2.48 (m, 3 H) 7.31 (s, 1 H).
Step C:
Under nitrogen atmosphere, a mixture of intermediate 11B (283.69 mg, 1.26 mmol),
intermediate 4A (500.00 mg, 900.15 μmol), (tert-butylphosphino)ferrocene palladium
chloride (58.67 mg, 90.02 μmol) and potassium phosphate trihydrate (479.44 mg, 1.80 mmol) in
ydrofuran (5.00 mL) and water (1.00 mL) was stirred at 65℃ for 12 hours. Then the reaction
solution was cooled to room temperature, filtered and concentrated. After the residue was
dissolved in water (50 mL) and extracted with ethyl acetate (100 mL*2), the organic phases were
combined and washed with brine (50 mL*2), dried over anhydrous sodium sulfate, filtered and
concentrated. The residue was purified by preparative thin layer chromatography to give
intermediate 11C (yellow solid, 266.00 mg, 51.51% . LCMS (ESI) m/z: 574.2 (M+1).
1HNMR (400 MHz, CHLOROFORM-d) δ ppm 1.27 - 1.34 (m, 6 H) 1.60 - 1.64 (m, 10 H) 1.60 -
1.65 (m, 10 H) 1.83 - 1.91 (m, 2 H) 1.95 (s, 1 H) 2.46 - 2.52 (m, 3 H) 3.95 - 4.01 (m, 2 H) 5.28 -
.31 (m, 2 H) 6.71 - 6.77 (m, 1 H) 6.94 - 6.97 (m, 1 H) 7.39 - 7.56 (m, 3 H) 7.63 - 7.68 (m, 1 H)
8.37 (s, 2 H) 8.47 (s, 2 H).
Step D:
Intermediate 11D was prepared according to the preparation method of intermediate 1F.
LCMS (ESI) m/z: 474.2 (M+1).
Step E:
Embodiment 11 was prepared according to the preparation method of embodiment 1.
LCMS (ESI) m/z: 488.2 (M+1). 1HNMR (400 MHz, DMSO-d6) δ ppm 1.37 (br d, J=10.54 Hz, 2
H) 1.79 (br d, J=10.04 Hz, 3 H) 2.11 (br s, 2 H) 2.26 - 2.31 (m, 3 H) 2.40 - 2.44 (m, 3 H) 2.89 - 2.97
(m, 2 H) 4.01 - 4.09 (m, 2 H) 5.25 (s, 2 H) 6.57 (d, J=9.41 Hz, 1 H) 7.45 (d, J=11.80 Hz, 3 H) 7.79
(dd, J=9.41, 2.64 Hz, 1 H) 8.20 - 8.26 (m, 2 H) 8.29 (s, 1 H) 8.53 - 8.56 (m, 1 H) 8.62 - 8.66 (m, 2
Embodiment 12
Step A:
ylamine (32.08 mg, 317.00 μmol, 43.94 μL) was added into a solution of phenyl
isocyanate (830.74 mg, 6.97 mmol) in nitroethane (261.77 mg, 3.49 mmol, 249.30 μL) and the
reaction solution was stirred at 50℃ for 30 minutes, then a solution of tributyl(ethynyl)stannane
(1.00 g, 3.17 mmol) in toluene (8.00 mL) was added into the reaction solution, followed by stirring
at 50℃ for 5 hours. Thin layer chromatography was used to detect the tion of the reaction.
Then water (100 mL) was added into the solution, which then was extracted with ethyl acetate (100
mL). The organic phase was then washed with brine (50 mL) and dried over anhydrous sodium
sulfate, filtered and concentrated with a rotary evaporator. The residue was purified by column
chromatography to give intermediate 12A w oily liquid, 700.00 mg, 42.13% yield). LCMS
(ESI) m/z: 373.14 (M+1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.82 - 0.85 (m, 9 H)
0.97 - 1.11 (m, 6 H) 1.20 - 1.34 (m, 12 H) 1.49 - 1.52 (m, 3 H) 7.18 - 7.20 (m, 1 H).
Step B:
ediate 12A (200 mg, 348.77 μmol) and Pd(PPh3)2Cl2 (25.27 mg, 36.01 μmol) were
added into a solution of intermediate 4A (200.00 mg, 360.06 μmol) in dioxane (4.00 mL) at 20℃,
then heated to 100℃ and stirred for 12 hours under nitrogen atmosphere. Thin layer
chromatography was used to detect the completion of the reaction. Then water (50 mL) was added
into the reaction solution and the solution was extracted with ethyl e (50 mL *2). The organic
phase was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and
trated with rotary evaporator. The residue was ed by column chromatography to give
intermediate 12B (yellow solid, 110.00 mg, yield). LCMS (ESI) m/z: 557.26 (M+1). 1H
NMR (400 MHz, CHLOROFORM-d) δ ppm 1.21 - 1.31 (m, 4 H) 1.40 (s, 9 H) 1.72 - 1.81 (m, 2 H)
1.89 - 1.98 (m, 1 H) 2.22 (s, 3 H) 2.70 (br s, 2 H) 3.88 (d, J=6.36 Hz, 2 H) 5.21 (s, 2 H) 6.02 (s, 1
H) 6.63 (d, J=9.54 Hz, 1 H) 7.33 - 7.37 (m, 1 H) 7.50 (dd, J=9.54, 2.57 Hz, 1 H) 7.57 - 7.64 (m, 1
H) 7.83 (d, J=2.32 Hz, 1 H) 8.23 - 8.31 (m, 2 H) 8.38 (s, 2 H).
Step C:
Intermediate 12C was prepared according to the preparation method of intermediate 1G.
LCMS (ESI) m/z: 457.21 (M+1).
Step D:
Embodiment 12 was prepared according to the preparation method of embodiment 1.
LCMS (ESI) m/z: 471.23 (M+1). 1H NMR (400 MHz, 6) δ ppm 1.14 - 1.21 (m, 2 H)
1.49 (br s, 2 H) 1.79 - 1.95 (m, 3 H) 1.99 (s, 2 H) 2.24 (s, 3 H) 2.38 - 2.38 (m, 1 H) 2.46 (s, 3 H)
3.12 (br d, J=10.92 Hz, 2 H) 5.29 (s, 2 H) 6.65 (s, 1 H) 7.47 (br s, 1 H) 7.82 - 7.90 (m, 1 H) 8.29 (br
s, 2 H) 8.63 (s, 2 H)
Assay 1: binding activity of c-MET enzyme assay
Reagents and consumables:
cMET (invitrogen PV3143)
Tracer 236 (Lot Number: 10815978)
Eu-Anti-His AB (MAb Anti 6HIS-K)
PerkinElmer ation Envison detection 665 nm and 615 nm
384-well plate _checkerboard (PerkinElmer #6007299)
Experimental principle:
The present experiment utilized the LanthaScreenTM Eu Kinase Binding Assay, as shown
in Figure 1, detection of Alexa Fluor conjugates or kinase combines tracer agent was done by adding
Eu labelled antibody. The binding of tracer agent and antibody and kinase leaded to high FRET
rd, while using kinase inhibitor instead of tracer agent would lead to loss of FRET.
mental method:
1) The antibody Eu-Anti-His AB, enzyme cMET, tracer agent Tracer236 were diluted.
2) Preparation of the compound: 10 mM test compound and reference compound were
diluted by 100% DMSO to 0.667mM, then fully automated microplate pretreatment system ECHO
was used for a 3-time dilution with 8 concentration gradients. Double duplicate wells were set and
each of them 75 nL.
3) The mixture of 7.5μL antibody (1/375 nM) and kinase (10 nM) was added to the
nd plate, followed by on of 7.5 μL Tracer (60 nM). Final concentration: cMET: 5
nM, Tracer 236: 30 nM, Eu-Anti-His AB (MAb Anti 6HIS-K): 1/750 nM.
4) After 60 mins of incubation at 4℃, Envision readings were performed with a multilabelled
microplate reader (data analysis of 665 nm/615 mm signal values with Prism 5; Ex
tion light: Laser mirror 446, Em tion light; 615 and 665 nM.
Experimental result: See Table 1.
Conclusion: the compounds of the present invention have a relatively strong inhibitory
effect on the c-MET enzyme.
Table 1
Test compound c-MET IC50 (nM) Test compound c-MET IC50 (nM)
Embodiment 1-2 1.09 Embodiment 7 15.50
Embodiment 2-2 9.33 Embodiment 8-2 3.79
Embodiment 4 6.16 Embodiment 10 69.50
Embodiment 5 2.90 Embodiment 11 5.00
Embodiment 6 4.37
Assay 2: Inhibitory effect assay on proliferation
Reagents and ables:
1) Cell culture: DMEM cell medium, fetal bovine serum, DPBS
2) Cell line: MHCC97-H
3) Detection reagent: live cell detection kit CellTiter-Glo
4) Other major consumables and reagents: compound dilution plate, intermediate plate,
test plate, DMSO
Experimental principle:
The amount of ATP directly reflects the number of cells and the state of the cells, thus the
number of living cells could be directly detected by quantitatively measuring ATP. The live cell
assay kit contains luciferase and its ate. With the presence of ATP, a stable optical signal
would be emitted by the luciferase catalyzed substrate. Thus the amount of ATP in the cell could
be ined by detecting the intensity of the signal. The light signal was proportional to the
amount of ATP in the cell, while the ATP was positively correlated with the number of living cells,
so that the proliferation in the cell could be detected. The assay plate used was analyzed by
Envision from PE Corporation.
Experimental method:
1. Preparation of the cell plates
MHCC97-H cells were seeded separately into ll plates, each of the well contains
500 cells. The cell plates were placed and ted in a carbon dioxide incubator overnight.
2. Preparation of the compound.
Echo was used for 4-time dilution and 9 concentration was prepared, ready for double
duplicate wells assay.
3. Compound treatment of cells
The compounds were transferred to cell plates at a starting concentration of 10μM. The
cell plates were incubated in a carbon dioxide tor for 3 days.
4. Detection
The Promegaer-Glo reagent was added into the cell plates and the plate was incubated at
room temperature for 10 mins to stabilize the luminescence signal. PerkinElmer Envision multilabel
analyzer was used for readings.
Experimental results: See Table 2:
Conclusion: the nds of the present invention exhibit good inhibitory activity
against MHCC97H cells.
Table 2
Test compound MHCC97H cell IC50 Test compound MHCC97H cell IC50
(nM) (nM)
Embodiment 1 8.80 Embodiment 7 22.30
Embodiment 2-2 13.80 Embodiment 9-2 22.10
Embodiment 3-2 19.0 Embodiment 10 166.00
ment 4 72.90 Embodiment 11 93.80
Embodiment 5 58.80 ment 12 51.40
Embodiment 6 32.90
Assay 3: pharmacodynamics assay of MHCC97H liver cancer cell subcutaneous xanograft
tumor model
Cell e:
MHCC97H cells were cultured in a single layer in-vitro. The culturing condition was
RPMI1640 medium supplemented with 10% nactivated fetal bovine serum, 1% penicillinstreptomycin
double antibody under 37℃, 5% carbon dioxide. Digestion and passage treatment
with trypsin-EDTA was done twice a week. When the cells are in the exponential growing phase,
the cells were collected, counted and inoculated.
Animal:
BALB/c nude mice, male. 6-8 weeks old, weighting 18-22 g.
Tumor inoculation:
0.2 mL of a cell suspension containing 5x10^6 MHCC97H was subcutaneously inoculated
into the right back of each mouse. Drugs were administrated by group after the average tumor
volume reached approximately 172 mm3. The experimental grouping and administrational
schedule are shown in the table below.
Aim of the assay: investigation of whether the tumor growth was inhibited, delayed or
cured. The diameters of the tumor was measured twice a week using vernier calipers. The
formula for ating the tumor volume is V = 0.5a×b2, and a and b represent the long and short
diameters of the tumor respectively. The antitumor effect (TGI) of the compounds was evaluated
by T-C (days) and T/C (%).
Experimental results: see in Table 3.
sion: the compounds of the present invention exhibit better tumor inhibitory
activity than nib in the pharmacodynamics assays of the aneous xenograft tumor model
of MHCC97H hepatoma cells.
Table 3: Evaluation of the anti-tumor efficacy of tested drugs on human liver cancer MHCC97H
cell xenograft model (calculations based on the 24th day-tumor-volume after stration of drug)
Tumor volume (mm3)a T/C TGI
group p value b
(24th day) (%) (%)
blank 2059±305 - - -
(Tepotinib) 255±5 12.4 95.6 <0.001
Embodiment 1-2 153±12 7.4 101.0 <0.001
Embodiment 8-2 161±6 7.8 100.6 <0.001
remarks:
a. average ± SEM.
b. p value was calculated based on the volume of the tumor.
The compounds of the present invention have better metabolic stability than tepotinib.
For example, the t1/2 of liver particle metabolism in the three species of human, rat and mice of
embodiment 1-2 are 62.1 min, 36.5 min and 49.1 min respectively. While under the same
conditions for Tepotinib in the three species of human, rat and mice, the t1/2 of liver particle
metabolism are 48.3 min, 10.5 min and 12.4 min respectively. The compounds of the present
invention have an extended half-time and action time on the target, an ed metabolic ity
and more ent inhibitory activity. The gation of ime would keep the concentration
in the blood for a longer time. Thus comparing to other medicament in the tumor treatment, the
compounds would reduce the dose and interval between doses so that the patient compliance would
be icantly improved.
Since when c-MET combined with HGF, it activated the MAPK, PI3K/AKT, CDc42/Rac1
and other pathways, leading to tumor cells survival and proliferation, y accelerated the tumor
growth rate. Thus the pyridone compound as c-Met inhibitor has great application prospects in
targeted therapeutic drugs such as liver , non-small cell lung cancer and gastric .
ally in treating liver cancer, this compound has a precise therapeutic effect on liver cancer
with high expression of c-Met. Therefore, the pyridone compound as c-Met inhibitor in the present
invention is expected to be a more therapeutically effective new drug than other similar products in
view of its remarkable inhibitory activity in vivo and in vitro, as well as its good metabolic stability.
Claims (17)
1. A compound represented by formula (I), or a ceutically acceptable salt thereof, wherein: R1 is selected from H or F; R2 is selected from H or CH3; when R2 is not H, the configuration of the carbon atom bonded to R2 is R or S; A is selected from the group consisting of phenyl, pyridyl, pyrazolyl, olyl, isothiazolyl and thiazolyl, each of which is ally substituted by 1, 2 or 3 R3; R3 is selected from CN, halogen, C(=O)NH2, or is selected from the group consisting of C1-6 alkyl, C1-6 heteroalkyl, and C3-6 cycloalkyl, each of which is optionally substituted by 1, 2 or 3 R0; R0 is selected from F, Cl, Br, I, OH, CN, NH2, C(=O)NH2, or is selected from the group consisting of C1-3 alkyl and C1-3 alkyl, each of which is optionally substituted by 1, 2 or 3 R’; R’ is selected from F, Cl, Br, I, CN, OH, NH2, CH3, CH3CH2, CF3, CHF2 or CH2F; the “hetero” in the C1-3 alkyl or C1-6 heteroalkyl is selected from the group consisting of -O-, -C(=O)NR’-, -C(=O)NH-, -NR’-, and -NH-; in any of the above cases, the number of the heteroatom or the heteroatomic group is independently selected from 1, 2 or 3.
2. The compound or the pharmaceutically acceptable salt thereof as defined in claim 1, wherein R0 is selected from F, Cl, Br, I, OH, CN, NH2, C(=O)NH2, CH3, CH3CH2, CF3, CHF2, CH2F, NH2CH2, (NH2)2CH, CH3O, CH3CH2O, CH3OCH2, CH3NH or (CH3)2N.
3. The compound or the pharmaceutically acceptable salt thereof as defined in claim 1 or claim 2, wherein R1 is H.
4. The compound or the ceutically acceptable salt thereof as defined in claim 1 or claim 2, wherein, R1 is F.
5. The compound or the pharmaceutically acceptable salt thereof as d in any one of claims 1 to 4, wherein, R2 is H.
6. The compound or the pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 4, n, R2 is CH3.
7. The compound or the pharmaceutically acceptable salt thereof as defined in claim 6, wherein, the configuration of the carbon atom bonded to R2 is R.
8. The compound or the pharmaceutically acceptable salt thereof as defined in claim 6, wherein, the configuration of the carbon atom bonded to R2 is S.
9. The compound or the pharmaceutically acceptable salt thereof as d in any one of claims 1 to 8, n, R3 is selected from CN, halogen, C(=O)NH2, or is selected from the group consisting of C1-3 alkyl and C1-3 heteroalkyl, each of which is optionally substituted by 1, 2 or 3 R0.
10. The compound or the pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 9, wherein, R3 is selected from CN, F, Cl, Br, CH3, CH3CH2, CF3, CHF2, CH2F, CH3O or C(=O)NH2.
11. The compound or the ceutically acceptable salt thereof as defined in any one of claims 1 to 10, wherein, A is selected from the group consisting of , , , , and , each of which is ally substituted by 1, 2 or 3 R3.
12. The compound or the pharmaceutically acceptable salt thereof as defined in any one of claim1 1 to 11, wherein, A is selected from the group consisting of , , , , , and .
13. The compound or the pharmaceutically able salt f as defined in any one of claims 1 to 12, wherein, A is selected from the group consisting of , , , , and .
14. The compound or the pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 13, wherein, A is selected from the group consisting of , , , , , , , and
15. The compound or the pharmaceutically acceptable salt thereof as defined in claim 1, wherein the compound is selected from the group consisting of
16. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt f as defined in any one of claims 1 to 15, and a ceutically acceptable carrier.
17. Use of the compound or the pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 15, or the pharmaceutical composition as defined in claim 16, in the manufacture of a medicament for treating a tumor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610954377 | 2016-10-27 | ||
CN201610954377 | 2016-10-27 | ||
PCT/CN2017/107964 WO2018077227A1 (en) | 2016-10-27 | 2017-10-27 | Pyridone compound as c-met inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ753020A NZ753020A (en) | 2021-08-27 |
NZ753020B2 true NZ753020B2 (en) | 2021-11-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7394074B2 (en) | therapeutic compounds | |
JP6380862B2 (en) | Condensed tricyclic amide compounds as inhibitors of multiple kinases | |
WO2022061251A1 (en) | Compounds and methods for kras modulation and indications therefor | |
KR101974673B1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
US9181264B2 (en) | Fused heteroaryls and their uses | |
CA3041164C (en) | Pyridone compound as c-met inhibitor | |
AU2015276699B2 (en) | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor | |
JP2017528475A (en) | Compounds and compositions as RAF kinase inhibitors | |
JP7328263B2 (en) | immunomodulatory compounds | |
JP2021522316A (en) | Dual ATM and DNA-PK inhibitors for use in antitumor therapy | |
JP6646044B2 (en) | Compounds and compositions as kinase inhibitors | |
JP2022515309A (en) | Substituted aryl compounds, their production methods and uses | |
WO2021202900A1 (en) | 1,6-naphthyridine compounds and methods for csk modulation and indications therefor | |
BR112020008991A2 (en) | pyridopyrimidine compounds that act as dual inhibitors of mtorc 1/2 | |
WO2023077259A1 (en) | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 | |
NZ753020B2 (en) | Pyridone compound as c-met inhibitor | |
CN112209925A (en) | RET selective inhibitor and preparation method and application thereof | |
TWI793877B (en) | Heterocyclic compound as diacrylglycerol kinases inhibitor and use thereof | |
WO2023036156A1 (en) | Dna-pk selective inhibitor, and preparation method therefor and use thereof | |
CN115572259A (en) | Arylsulfonamide compounds and uses thereof |